Patent intelligence · US
US 11384337
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
Patent details — US 11384337
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 12, 2022
- Expiration
- Jul 7, 2042
- Applicant
- Iovance Biotherapeutics, Inc.
- Claims
- 28
- CPC classes
- A61K, A61K2039/5158, A61K35/17, A61K39/0011
Quick answer
US 11384337 (Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy) is held by Iovance Biotherapeutics, Inc.. Status: granted. Granted Jul 12, 2022. Expires Jul 7, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Iovance Biotherapeutics, Inc.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K2039/5158, A61K35/17, A61K39/0011
More from Iovance Biotherapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12343380
Expansion of TILs utilizing AKT pathways inhibitors
granted -
US 12280140
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
granted -
US 12233075
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
granted -
US 12230378
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
granted -
US 12226434
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 12230379
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
granted -
US 12194061
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 12188048
Restimulation of cryopreserved tumor infiltrating lymphocytes
granted
Frequently asked questions
What is US patent 11384337?
US 11384337 (Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy) is held by Iovance Biotherapeutics, Inc.. Status: granted. Granted Jul 12, 2022. Expires Jul 7, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11384337?
Iovance Biotherapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 94 pharmaceutical patents for this assignee.
When does US 11384337 expire?
Our index shows an expiration date of Jul 7, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.